Gadoquatrane showed pediatric safety and pharmacokinetic profiles similar to adults in a study, supporting use as a low-dose ...

(RTTNews) - GE Healthcare said Monday that the U.S. Food and Drug Administration approved Clariscan, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE Healthcare portfolio ...

UCHealth said it's the first to offer a kind of mammogram in Colorado that could be a game changer when it comes to breast cancer.

Patients with stage 1 or 2, hormone receptor (HR)-negative breast cancer had similar five-year rates of locoregional ...

Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...

Dec. 5, 2003 -- Intravenous and intra-articular enhanced magnetic resonance imaging (MRI) are comparable for evaluating meniscal tears, and both are better than nonenhanced MRI, according to the ...

Onsite Women's Health is exploring a new imaging technology that could help patients avoid the long waits, high costs and ...

Patients with stage I or II hormone receptor-negative breast cancer do not benefit from preoperative breast MRI, according to ...

MRI with a 15-channel dental coil detects bone invasion with superior accuracy in patients with head and neck cancer, a ...

Preparing for a Magnetic Resonance Imaging (MRI) scan involves several essential steps to ensure the procedure is both safe and yields the clearest possible images.

CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...